ClinicalTrials.gg
RecruitingNCT07600749Updated Oct 6, 2026

Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)

A Phase 1 interventional study of MK-4884 in Malignant Neoplasm, sponsored by Merck Sharp & Dohme LLC. Recruiting at 10 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Oct 6, 20262 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Researchers are looking for new ways to treat certain types of advanced and/or metastatic solid tumors.

The main goal of this study is to learn about the safety of different doses of MK-4884 and if participants tolerate them.

02

Conditions studied

  • Malignant Neoplasm

Browse trials for

03

In context

Neoplasms

10,834 studies on the registry are indexed under Neoplasms; 2,323 are open to participants now.

This study's planned enrollment of 120 is above the median of 60 across 7,714 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a or cytologically confirmed diagnosis of 1 of the following unresectable (locally advanced) and/or advanced () solid tumors:
  • Colorectal carcinoma (CRC)
  • Renal cell carcinoma (RCC) that contains a clear cell component (with or without sarcomatoid and/or rhabdoid features)
  • Nonsquamous non-small cell lung cancer (NSCLC)
  • Biliary tract cancer (BTC) (intra-or extrahepatic cholangiocarcinoma (CCA)) or gallbladder cancer (GBC)
  • Has by 1.1 (RECIST 1.1)
  • Has adequate organ function
  • Participants with (HIV) infection must have well controlled HIV on stable antiretroviral therapy (ART) for at least 4 weeks
  • Participants who are surface antigen (HBsAg) positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load
  • Participants with a history of virus (HCV) infection are eligible if HCV viral load is undetectable

Exclusion criteria

Exclusion Criteria:

  • Has gastrointestinal malabsorption, a surgical procedure or a condition that could affect the absorption of the study drug
  • Has a history of cardiac, cardiovascular and/or cerebrovascular disease
  • Has a serious nonhealing wound, ulcer, or bone fracture
  • Has an active infection(s) requiring systemic therapy
  • -infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
  • Known additional that is progressing or has required active treatment within the past 2 years
  • Has known active central nervous system (CNS) and/or carcinomatous meningitis
  • Has a history of stem cell/solid organ transplant
  • Has not adequately recovered from major surgery
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    MK-4884 Dose Escalation Schedule A

    Participants will receive MK-4884 at varying dose levels until any of the criteria for discontinuation of the study intervention are met.

    Drug: MK-4884

  • Experimental
    MK-4884 Dose Escalation Schedule B

    Participants will receive MK-4884 at varying dose levels until any of the criteria for discontinuation of the study intervention are met.

    Drug: MK-4884

Interventions

  • DrugMK-4884

    Oral Administration

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs)

    DLT is defined as the occurrence of protocol-specified toxicities, unless clearly related to disease progression or intercurrent illness.

    Time frame: Up to approximately 21 days

  2. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants with experience an AE will be reported.

    Time frame: Up to approximately 39 months

  3. Number of Participants Who Discontinue Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinued study treatment due to an AE will be reported.

    Time frame: Up to approximately 39 months

Secondary outcomes

  1. Area Under the Concentration-Time Curve (AUC) of MK-4884

    Blood samples will be collected to determine the AUC of MK-4884 in plasma.

    Time frame: At designated timepoints (up to approximately 15 days)

  2. Maximum Plasma Concentration (Cmax) of MK-4884

    Blood samples will be collected to determine the Cmax of MK-4884 in plasma.

    Time frame: At designated timepoints (up to approximately 15 days)

  3. Trough Plasma Concentration (Ctrough) of MK-4884

    Blood samples will be collected to determine the Ctrough of MK-4884 in plasma.

    Time frame: At designated timepoints (up to approximately 39 months)

  4. Time to Maximum Plasma Concentration (Tmax) of MK-4884

    Blood samples will be collected to determine the Tmax of MK-4884 in plasma.

    Time frame: At designated timepoints (up to approximately 15 days)

  5. Apparent Terminal Half-life (t½) of MK-4884

    Blood samples will be collected to determine the t1/2 of MK-4884 in plasma.

    Time frame: At designated timepoints (up to approximately 15 days)

07

Study locations

10 of 10 sites recruiting
  • Siteman Cancer Center ( Site 0153)
    St Louis, Missouri 63108, United States
    Recruiting
    • Study Coordinator · Contact314-273-8602
  • NEXT Oncology ( Site 0151)
    San Antonio, Texas 78229, United States
    Recruiting
    • Study Coordinator · Contact210-568-4397
  • Princess Margaret Cancer Centre ( Site 0004)
    Toronto, Ontario M5G 2M9, Canada
    Recruiting
    • Study Coordinator · Contact416-596-4200
  • Centre Hospitalier de l'Université de Montréal-Unit for Innovative Therapies ( Site 0002)
    Montreal, Quebec H2X 0A9, Canada
    Recruiting
    • Study Coordinator · Contact514-890-8000
  • Rambam Health Care Campus ( Site 0051)
    Haifa, 3109601, Israel
    Recruiting
    • Study Coordinator · Contact+97247776731
  • Rabin Medical Center ( Site 0053)
    Petah Tikva, 4941492, Israel
    Recruiting
    • Study Coordinator · Contact+97239377377
  • National Cancer Center Hospital ( Site 0201)
    Chūō, Tokyo 104-0045, Japan
    Recruiting
    • Study Coordinator · Contact+81-3-3542-2511
  • Cantonal Hospital St.Gallen ( Site 0101)
    Sankt Gallen, Canton of St. Gallen 9007, Switzerland
    Recruiting
    • Study Coordinator · Contact+41 55 285 41 11
  • CHUV (centre hospitalier universitaire vaudois) ( Site 0103)
    Lausanne, Canton of Vaud 1011, Switzerland
    Recruiting
    • Study Coordinator · Contact+41213140155
  • Ospedale Regionale Bellinzona e Valli ( Site 0104)
    Bellinzona, Canton Ticino 6500, Switzerland
    Recruiting
    • Study Coordinator · Contact0041 091 811 91 11
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Oct 2029, 39 months after the start.

Of 676 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's planned 39 months is close to that.

Counting every sponsor, half of 903 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2026
First posted
May 22, 2026
StartActual
Jun 18, 2026
Primary completionEst.
Oct 4, 2029
CompletionEst.
Oct 4, 2029
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (1 Canada, 1 United States)
  • Princess Margaret Cancer Centre ( Site 0004) · Toronto, Canada
  • Siteman Cancer Center ( Site 0153) · St Louis, United States
across 2 updates, Sep 25, 2026 – Oct 6, 2026
Show all 2 updates
  1. Oct 6, 2026
    1 site added
    Show site
    • Siteman Cancer Center ( Site 0153) · St Louis, United States
    + 1 other change: verification date
  2. Sep 25, 2026
    1 site added
    Show site
    • Princess Margaret Cancer Centre ( Site 0004) · Toronto, Canada

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07600749
Responsible party
Sponsor
First posted
May 22, 2026
Start date
Jun 18, 2026
Primary completion
Oct 4, 2029 (estimated)
Completion
Oct 4, 2029 (estimated)
Last update
Oct 6, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion